 LIbrary
of Slides and Posters
Switching
from Combivir [CBV] (AZT/3TC) to Truvada [TVD] (TDF/FTC) Preserves Limb Fat: Results
of a DEXA Sub-Study of a 48 Week Randomised Study
G Moyle and others.
CROI 2008.
DELPHI Darunavir
EvaLuation in Pediatric HIV-1- Infected treatment-experienced patients
R
Bologna and others. CROI 2008.
Characterization
of virologic failures on darunavir/ritonavir in the randomized, controlled, Phase
III TITAN trial in treatment-experienced patients
S De Meyer and others.
CROI 2008.
Pharmacokinetic-pharmacodynamic
analyses of once-daily darunavir in the ARTEMIS study
V Sekar and others.
CROI 2008.
Long-acting TMC278,
a parenteral depot formulation delivering sustained NNRTI plasma concentrations
in preclinical and clinical settings
G van’t Klooster and others. CROI
2008.
DUET-1:Week 48 results
of a Phase III randomized double-blind trial to evaluate the efficacy and safety
of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected
patients
R Haubrich and others. CROI 2008.
DUET-2:Week
48 results of a Phase III randomized double-blind trial to evaluate the efficacy
and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced
HIV-1-infected patients
M Johnson and others. CROI 2008.
Pharmacokinetics
of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children
between 6 and 17 years, inclusive
T Kakuda and others. CROI 2008.
Pharmacokinetics
and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced
HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2
T
Kakuda and others. CROI 2008.
Prevalence
of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of
clinical isolates
G Picchio and others. CROI 2008.
Efficacy
and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination
with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study
K
Smith and others. CROI 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Resistance Profile
of the Integrase Inhibitor S/GSK-364735
T Yoshinaga and others. CROI 2008.
Copyright GlaxoSmithKline. Used with permission, 2008.
A
phase I study to explore the activity and safety of SCH 532706, a small molecule
chemokine receptor-5 (CCR5) antagonist in HIV-1 infected subjects.
S Pett
and others. CROI 2008
Effect
of Virus Concentration on in vitro Measurement of Phenotypic Resistance to the
CCR5 Antagonist Vicriviroc.
C Buontempo and others. CROI 2008.
The Effect of
Vicriviroc Upon Viral Load in HIV/HCV Co-infected Patients Receiving a Ritonavir-containing
Protease Inhibitor Regimen.
G Fätkenheuer and others. CROI 2008.
48-Week
Results from BENCHMRK-1, a Phase III Study of Raltegravir (RAL) in Patients Failing
Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1.
D Cooper
and others. CROI 2008.
48-Week
Results from BENCHMRK-2, a Phase III Study of Raltegravir (RAL) in Patients Failing
Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1.
R Steigbige
and others. CROI 2008.
Vicriviroc,
a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral
Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results.
B
Zingman and others. CROI 2008.
Vicriviroc
in Combination Therapy With an Optimized Antiretroviral Regimen for Treatment-Experienced
Subjects: The VICTOR-E1 Trial.
B Zingman and others. CROI 2008.
Bone
Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation:
A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ ritonavir
(LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy.
T
Brown and others. CROI 2008.
Study
M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study
of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID),
Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve
(ARV) HIV-1 Infected Subjects.
J Gathe and others. CROI 2008.
Prevalence,
Mutational Patterns and Phenotypic Correlates of the L76V Protease Mutation in
Relation to LPV Associated Mutations.
M Norton and others. CROI 2008.
Lopinavir/ritonavir
(LPV/r) 500/125 mg BID Plus Efavirenz Approximate the Pharmacokinetic Exposure
of LPV/r 400/100 mg BID Administered Alone in Healthy Adult Subjects.
J
Ng and others. CROI 2008.
Impact
of a 48-week Lopinavir/r Monotherapy on HIV1-DNA in Blood Cells in the MONARK
Trial.
V Avettand-Fenoel and others. CROI 2008.
Multicenter,
Retrospective Study of Incidence and Predictors of Adverse Events Associated With
Nevirapine Use in a Cohort of Pregnant and Nonpregnant Women Treated at 3 Urban
HIV Clinics in the United States
E Aaron and others. CROI 2008.
Pharmacokinetic
Interaction Between Tipranavir/Ritonavir and Rosuvastatin
P Pham and others.
CROI 2008.
|
